Lung Fibrosis after COVID-19: Treatment Prospects
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398080/
Based on these data, the incidence rate of post-COVID lung fibrosis can be estimated at 2–6% after moderate illness.
What is worse, there are reasons to believe that fibrosis may become one of the major long-term complications of COVID, even in asymptomatic individuals. Currently, despite the best efforts of the global medical community, there are no treatments for COVID-induced pulmonary fibrosis. In this review, we analyze the latest data from ongoing clinical trials aimed at treating post-COVID lung fibrosis and analyze the rationale for the current drug candidates.
Comments
Post a Comment